secwatch.observer — SEC 8-K summary
======================================

Issuer:     Adaptive Biotechnologies Corp (ADPT)
CIK:        0001478320
Form:       8-K
Filed at:   2023-02-14T23:59:59+00:00
Accession:  0000950170-23-002786
Event type: earnings
Sentiment:  positive
Materiality: 0.75
Item codes: 2.02, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Adaptive Biotechnologies Q4 revenue $55.2M (+46% YoY); guides FY2023 rev $205M-$215M
--------------------------------------------------------------------------------

- Full year 2022 revenue $185.3M (+20% YoY); MRD revenue $87.1M (+32%), Immune Medicine $98.2M (+11%).
- clonoSEQ test volume Q4 up 54% to 10,526 tests; full year up 51% to 36,871 tests.
- Net loss Q4 $40.2M vs $61.4M; adjusted EBITDA loss $19.6M vs $44.9M YoY.
- 2023 revenue guidance $205M-$215M; operating expenses expected below $385.5M.
- Long-term targets: 20-30% revenue CAGR, positive adjusted EBITDA in 2025, cash flow breakeven in 2026.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1478320/000095017023002786/0000950170-23-002786-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1478320/000095017023002786/adpt-20230214.htm
  HTML page:      https://secwatch.observer/filing/0000950170-23-002786

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer